Ally Bridge Group’s Relay Therapeutics RLAY Stock Holding History

Ally Bridge Group’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-626,058	Closed	-$4.43M	–	35
2024 Q3	$4.43M	Buy	+626,058	New	+$4.68M	2.37%	25

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Ally Bridge Group's RLAY Position: Q4 2024 in Review

Ally Bridge Group sold out of Relay Therapeutics (RLAY) in Q4 2024, closing a stake of 626,058 shares — an estimated $4.43M sold.

Ally Bridge Group first reported a position in RLAY in Q3 2024 and held it in 1 quarter. The position peaked at $4.43M in Q3 2024. 199 funds tracked by Wall St. Rank hold RLAY as of Q4 2024.

Ally Bridge Group reported no remaining Relay Therapeutics position as of Q4 2024 after selling out during the quarter.
Ally Bridge Group sold 626,058 Relay Therapeutics shares in Q4 2024, an estimated $4.43M.
Ally Bridge Group first reported a position in Relay Therapeutics in Q3 2024 and held it in 1 quarter.
Ally Bridge Group's Relay Therapeutics position peaked at $4.43M in Q3 2024.
199 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2024.

Based on Ally Bridge Group's 13F filing for Q4 2024, filed 14 Feb 2025.